FDA recommends pause of Johnson & Johnson COVID-19 vaccine after blood clot cases

Volgens die FDA, there have been six reported cases of the rare and severe type of blood clot in over 6.8 miljoen Johnson & Johnson vaccine recipients.

“Nou dadelik, these adverse events appear to be extremely rare,” the agency said on Twitter. “Treatment of this specific type of blood clot is different from the treatment that might typically be administered. CDC will convene a meeting of the Advisory Committee on Immunization Practices (ACIP) on Wednesday to further review these cases and assess their potential significance. FDA will review that analysis as it also investigates these cases.

Egter, until that review is completed, the FDA isrecommending this pause.

This is important to ensure that the health care provider community is aware of the potential for these adverse events and can plan due to the unique treatment required with this type of blood clot,” the FDA said on Twitter.


A 10 am. press conference is planned for Tuesday.

This is a developing story please continue to check back for updates.

Kommentaar gesluit.